Inhibition of renin secretion by angiotensin II receptor blockage?  by Krämer, Bernhard K. et al.
Letters to the Editor1612
one member only had IgAN and one (or two relatives) tive treatments were very similar (i.e., 1.14 vs. 0.94 ng/mL/
had HSP. hour). Second, sodium intake was high and uncontrolled,
In our opinion, the possibility of such familial cases of allowing a lower baseline sodium excretion (intake)
IgAN and HSP can also be considered as another link before losartan treatment compared to placebo treat-
between the two diseases. ment ( sodium excretion 37 mEq/24 hours) and a higher
sodium excretion at the end of losartan treatment ( so-
Micheline Levy dium excretion 12 mEq/24 hours). Furthermore, the cir-
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Therefore, the most plausible explanation for the
plasma renin data obtained by Agarwal [1] may be meth-REFERENCES
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expression severalfold from baseline [2]. Furthermore,
both 100 mg losartan and 80 mg quinalapril given for 10
days at this constant dose increased plasma renin activity
Reply from the author3- to 4-fold in 25 normotensive subjects on a controlled
I agree with Kra¨mer et al that the increase in plasma(low) sodium intake [3]. Finally, Stergiou et al recently
renin activity (PRA) with add-on losartan therapy wasdemonstrated that the addition of 80 mg valsartan for 5
unexpected [1]. However, I am unaware of any data inweeks to a maximal dose of chronic benazepril (20 mg
the population of patients that was studied to refute thosefor 6 weeks) significantly increased plasma renin activity
findings. Brown, Agirbasli, and Vaughan compared an-in 20 patients with primary hypertension [4].
giotensin-converting enzyme (ACE) inhibitors with an-The above results of Agarwal [1] may be explained by
giotensin II receptor blocker but did not study the combi-several shortcomings of this study. First, baseline plasma
nation in normotensive, sodium-restricted volunteers [2].renin activity before losartan treatment was 204% (!) of
In the study by Stergiou et al, benazepril was used in abaseline plasma renin activity before placebo treatment,
submaximal dose (20 mg/day) in patients with essentialwhereas plasma renin activities at the end of the respec-
hypertension [3]. In contrast, our patients received lisino-
pril for an average of 18 months in a dose of 40 mg/day
prior to participation in the trial. Such a dose is truly max- 2001 by the International Society of Nephrology
